title: Hypopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanoma.
abstract: BACKGROUND
  Reports of vitiligo associated with metastases and rare cases of spontaneous regression of disease have fueled enthusiasm for immunologic approaches to the treatment of advanced melanoma. More recent strategies have focused on using antigen-presenting dendritic cells as vaccines.
  
  
  METHODS
  We observed 3 cases of leukoderma associated with a novel adenovirus-mediated gp100/MART-1-transduced dendritic cell (MART indicates melanoma antigen recognized by T cells). All 3 patients had advanced metastatic melanoma. Despite the development of this leukodermic response, all patients experienced disease progression while under treatment.
  
  
  CONCLUSIONS
  We provide the initial evidence for effective induction of a leukodermic response with a gp100/MART-1-transduced dendritic cell vaccine.
authors.affiliation: Department of Dermatology, Massachusetts General Hospital, Boston, MA 02114, USA. htsao@partners.org
authors.forename: Hensin
authors.initials: H
authors.lastname: Tsao
authors.forename: Peri
authors.initials: P
authors.lastname: Millman
authors.forename: Gerald P
authors.initials: GP
authors.lastname: Linette
authors.forename: F Stephen
authors.initials: FS
authors.lastname: Hodi
authors.forename: Arthur J
authors.initials: AJ
authors.lastname: Sober
authors.forename: Mark A
authors.initials: MA
authors.lastname: Goldberg
authors.forename: Frank G
authors.initials: FG
authors.lastname: Haluska
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm; D001707:Biopsy, Needle; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D017496:Hypopigmentation / Q000139:chemically induced* / Q000175:diagnosis; D058965:MART-1 Antigen; D008297:Male; D008545:Melanoma / Q000276:immunology / Q000473:pathology / Q000517:prevention & control* / Q000556:secondary; D008562:Membrane Glycoproteins / Q000008:administration & dosage / Q000009:adverse effects*; D009363:Neoplasm Proteins / Q000008:administration & dosage / Q000009:adverse effects*; D009367:Neoplasm Staging; D018570:Risk Assessment; D012878:Skin Neoplasms / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D058951:gp100 Melanoma Antigen
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D058965:MART-1 Antigen; C548667:MLANA protein, human; D008562:Membrane Glycoproteins; D009363:Neoplasm Proteins; C548637:PMEL protein, human; D058951:gp100 Melanoma Antigen